Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

Abstract Previously, we found that patients with estrogen receptor (ER)-positive, HER2-low breast cancer are resistant to neoadjuvant chemotherapy (NACT) and have worse outcomes than those who achieve pathological complete response (pCR) after NACT. This study aimed to investigate the prognosis and...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-05-01
Col·lecció:	Scientific Reports
Matèries:	Neoadjuvant chemotherapy Breast cancer Estrogen receptor HER2-low Prognosis
Accés en línia:	https://doi.org/10.1038/s41598-024-62592-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!